Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial

Primary efficacy analysis of single-arm phase 2 NCT03575611 in oligometastatic clear-cell renal cell carcinoma, with no concurrent systemic therapy. Of 121 patients enrolled (intention-to-treat), 120 received definitive radiotherapy to at least one metastasis (per-protocol). Median progression-free survival was 17.7 months (95% CI 14.9–22.4) in the per-protocol population, and median systemic therapy-free survival was 34.0 months (95% CI 28.3–54.1) in the intention-to-treat population. The median and the lower bound of its 95% CI exceeded the prespecified 24-month systemic therapy-free survival target.

Lancet OncolPubMed 40915303DOI 10.1016/S1470-2045(25)00380-8